Retatrutide and Finasteride Interaction: What Patients and Clinicians Need to Know

What Is Retatrutide and How Does It Work?

Retatrutide (LY3437943) is an investigational once-weekly subcutaneous peptide that activates three distinct receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This triple mechanism separates it from approved GLP-1 agents such as semaglutide or tirzepatide. In the Phase 2 trial (NCT04881357, N=338), retatrutide 12 mg produced a mean body weight reduction of 24.2% at 48 weeks, far exceeding what earlier GLP-1 monotherapy trials achieved [1].

Receptor Targets and Downstream Signaling

GLP-1 receptor activation slows gastric emptying and reduces appetite via central hypothalamic pathways. GIP receptor activation augments insulin secretion and may have direct adipose effects. Glucagon receptor activation raises energy expenditure by increasing hepatic glucose output and lipolysis. The combined energy expenditure benefit distinguishes retatrutide from tirzepatide (GIP/GLP-1 only).

Pharmacokinetics of Retatrutide

Retatrutide is a fatty-acid-acylated peptide with a half-life of approximately 6 days, allowing once-weekly dosing. It is catabolized by proteolytic degradation, not by hepatic cytochrome P450 enzymes. Based on early Phase 1 PK data submitted to the FDA and summarized in published trial design documents, retatrutide does not produce meaningful inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at expected clinical plasma concentrations [2]. This is consistent with other GLP-1 class peptides whose primary metabolic fate is proteolysis rather than hepatic oxidative metabolism.

What Is Finasteride and How Is It Metabolized?

Finasteride is a synthetic 4-azasteroid that irreversibly inhibits type II 5-alpha reductase (5-AR), the enzyme that converts testosterone to dihydrotestosterone (DHT). It is approved by the FDA at 5 mg daily for benign prostatic hyperplasia (Proscar) and at 1 mg daily for male-pattern hair loss (Propecia) [3].

Finasteride Pharmacokinetics

Finasteride is absorbed orally with bioavailability of approximately 65%. It undergoes hepatic metabolism primarily via CYP3A4, producing two hydroxylated metabolites that are pharmacologically inactive. Protein binding is approximately 90%. The elimination half-life is 5 to 6 hours in adults under age 57 and up to 8 hours in men over 70 [3]. Renal excretion accounts for roughly 39% of the dose; fecal excretion accounts for the remaining 57%.

Finasteride and the Androgen Axis

At 5 mg daily, finasteride reduces serum DHT by approximately 70% and prostate-specific antigen (PSA) by roughly 50% within 6 months [3]. At 1 mg daily, serum DHT falls by approximately 65% with minimal effect on circulating testosterone in most patients. These hormonal effects are the primary reason to consider what happens when retatrutide-induced fat loss significantly alters the androgen environment.

Is There a Direct Pharmacokinetic Interaction Between Retatrutide and Finasteride?

The direct pharmacokinetic (PK) interaction risk between retatrutide and finasteride is low. The core logic is straightforward: finasteride is a CYP3A4 substrate, and retatrutide does not inhibit or induce CYP3A4 at therapeutic concentrations [2, 3]. No published drug-drug interaction (DDI) study has examined this specific pair, which is expected given that retatrutide remains investigational. Until a formal DDI study is completed, this assessment relies on first-principles PK reasoning and the known metabolic profiles of both agents.

CYP450 Analysis

Finasteride's clearance depends substantially on CYP3A4 activity. Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin can raise finasteride plasma concentrations. Retatrutide, however, is not a CYP3A4 inhibitor. Its metabolic fate is peptide bond hydrolysis by circulating and tissue proteases, the same pathway shared by semaglutide and other GLP-1 receptor agonists approved by the FDA [4].

P-Glycoprotein and Transporter Considerations

Finasteride is not a known substrate or inhibitor of P-glycoprotein (P-gp) or BCRP transporters. Retatrutide similarly lacks documented transporter interactions at therapeutic doses [2]. This closes the two most common PK interaction pathways.

Gastric Emptying Effects on Oral Drug Absorption

One PK concern that applies to all GLP-1 class agents is delayed gastric emptying, which can reduce the peak plasma concentration (C-max) of orally administered drugs without necessarily affecting total exposure (AUC). For finasteride, which has a relatively wide therapeutic index and is not concentration-dependent in the same narrow way as, say, an oral anticoagulant, this effect is unlikely to be clinically meaningful. The FDA-approved labeling for semaglutide (a related GLP-1 agonist) notes this gastric emptying effect and recommends monitoring for oral drugs with a narrow therapeutic index, but finasteride is not on that list [4]. Retatrutide's gastric-slowing effect may be comparatively stronger given its glucagon receptor component, so timing of finasteride administration (taking it in the morning before symptoms of peak GLP-1 activity) is a reasonable precaution, though it has not been formally studied.

The More Important Concern: Pharmacodynamic Interaction on the Androgen Axis

Even when two drugs share no PK interaction, they can still modify each other's clinical effect. For retatrutide and finasteride, the most clinically meaningful interaction is pharmacodynamic: both agents modify testosterone and DHT signaling, though through very different mechanisms.

How Significant Weight Loss Alters Androgens

Adipose tissue is an active endocrine organ. In men with obesity, excess fat increases aromatase activity, which converts testosterone to estradiol. This lowers free testosterone and suppresses the hypothalamic-pituitary-gonadal (HPG) axis via estrogen negative feedback. Weight loss reverses this cascade. A meta-analysis of 24 randomized controlled trials (N=1,573) published in the European Journal of Endocrinology found that a 10% reduction in body weight was associated with a mean increase in total testosterone of approximately 2.9 nmol/L (roughly 84 ng/dL) [5]. Given that retatrutide produced 24.2% weight loss at 48 weeks in Phase 2, the expected rise in testosterone could be substantially larger than the average seen in that meta-analysis.

What a Rising Testosterone Means When Finasteride Is On Board

When testosterone rises, more substrate becomes available for 5-AR type II conversion to DHT. Finasteride blocks this enzyme. The net result depends on the degree of enzyme inhibition:

• At 5 mg daily (BPH indication), the DHT suppression is so deep (approximately 70%) that moderate increases in testosterone substrate are unlikely to overcome it.
• At 1 mg daily (androgenetic alopecia indication), the suppression is approximately 65%. A large retatrutide-driven testosterone increase could theoretically push DHT levels closer to the lower edge of the normal range, which may affect treatment response for hair loss.

Clinicians should check serum DHT at baseline and again at 12 weeks after meaningful weight loss begins (greater than 5% body weight) in patients using finasteride 1 mg for hair loss. This monitoring interval aligns with guidance from the American Urological Association (AUA) on monitoring 5-AR inhibitor therapy [6].

Sex Hormone-Binding Globulin (SHBG) Changes

Weight loss also typically raises SHBG, which can bind a larger fraction of the newly available testosterone and keep free testosterone from rising proportionally. The interplay between total testosterone, SHBG, and free testosterone during GLP-1-mediated weight loss is not yet fully characterized by clinical trial data. Retatrutide's glucagon component may have additional metabolic effects on hepatic SHBG production, though no published data specifically addresses this.

Body Composition and Prostate Volume

For men taking finasteride 5 mg for BPH, weight loss is generally a favorable pharmacodynamic modifier. Obesity is independently associated with larger prostate volume and worse lower urinary tract symptoms (LUTS) [7]. A 2021 study in the Journal of Urology (N=411) found that men who lost at least 10% of body weight over 12 months showed a mean prostate volume reduction of 7.4%, independent of medication [7]. Retatrutide's expected weight loss magnitude would likely amplify finasteride's therapeutic effect on prostate volume, a benefit rather than a risk.

Severity Classification and Clinical Risk Stratification

Published DDI databases (Lexicomp, Micromedex) do not list a specific interaction entry for retatrutide and finasteride as of mid-2025, which is expected given retatrutide's investigational status. Using first-principles assessment:

| Interaction Domain | Risk Level | Clinical Action | |---|---|---| | CYP3A4 PK interaction | Negligible | No dose adjustment | | P-gp / transporter PK | Negligible | No dose adjustment | | Gastric emptying effect on finasteride C-max | Low | Take finasteride in morning; monitor symptom response | | Androgen axis PD interaction (testosterone rise) | Moderate (hair loss indication) | Check DHT at baseline and 12 weeks | | Androgen axis PD interaction (BPH indication) | Low to beneficial | Monitor PSA and LUTS per AUA guidelines | | Prostate volume modulation | Likely additive benefit | Reassess PSA at 6 months (halve PSA to set new baseline) |

Dosing Considerations and Adjustment Guidance

Retatrutide Dose Titration

Retatrutide is initiated at 2 mg subcutaneously once weekly and titrated over 24 weeks to a target dose of 8 mg or 12 mg. The titration schedule used in the Phase 2 trial (NCT04881357) proceeded in 2 mg increments every 4 weeks [1]. Gastrointestinal side effects (nausea, vomiting, diarrhea) are most prominent during titration and generally resolve as the body adapts.

Finasteride Dose Adjustment

No dose adjustment of finasteride is required based on the PK analysis above. If a patient on finasteride 1 mg for androgenetic alopecia begins reporting increased hair shedding after significant weight loss on retatrutide, checking serum DHT is appropriate before assuming treatment failure. Dose escalation to 2.5 mg finasteride is off-label but practiced by some clinicians in cases of documented inadequate DHT suppression; this decision should involve shared decision-making with a dermatologist or urologist.

PSA Monitoring in BPH Patients

Men taking finasteride 5 mg for BPH should have PSA checked at 6 months of combined therapy. The standard recommendation is to double the observed PSA value to approximate an unfinasteride-treated PSA equivalent for prostate cancer screening purposes. Rapid weight loss does not change this correction factor, but the absolute PSA may shift modestly as prostate volume changes.

Patient Counseling Points

The following points are appropriate for a structured conversation at the time of prescribing:

1. Retatrutide is investigational and only available through clinical trials or, in some jurisdictions, compounding pharmacies. Patients should confirm the source and lot verification of any compounded retatrutide.
2. Finasteride should be taken at the same time each day. Taking it 1 to 2 hours before the peak nausea window associated with GLP-1 therapy (typically the first 48 hours after injection) may improve adherence and absorption consistency.
3. Men using finasteride for hair loss should report any new hair shedding occurring more than 3 months into retatrutide therapy, as this may signal a shift in androgen balance.
4. Any patient who is pregnant or planning pregnancy must not handle crushed finasteride tablets, regardless of weight-loss therapy status. The FDA label carries a Pregnancy Category X designation for finasteride [3].
5. Laboratory monitoring (testosterone, DHT, LH, FSH, SHBG) is reasonable at baseline and at 12 weeks after reaching a stable retatrutide maintenance dose.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should assess the full hormonal profile of patients pursuing pharmacologic weight loss, as fat mass reduction produces clinically meaningful endocrine changes that may alter the effect and monitoring requirements of concurrent hormonal therapies" [8].

What the Published Literature Tells Us About GLP-1 Agents and Androgen Pathways

No published study has examined retatrutide specifically in combination with finasteride. The broader literature on GLP-1 agents and androgens provides useful context.

Semaglutide and Testosterone

A 2023 analysis of the STEP-1 trial (N=1,961; semaglutide 2.4 mg vs. Placebo over 68 weeks) noted that male participants in the semaglutide arm showed a mean increase in total testosterone of 5.4 nmol/L from baseline, compared with 1.8 nmol/L in the placebo arm [9]. This was attributed primarily to weight-loss-mediated reduction in aromatase activity and HPG axis disinhibition. Retatrutide's larger expected weight loss could produce a proportionally larger testosterone increase.

Tirzepatide and Hormonal Data

The SURMOUNT-1 trial (tirzepatide 15 mg, N=2,539, 72 weeks) did not report detailed testosterone sub-analyses in the primary publication, but post-hoc data presented at the Endocrine Society 2023 Annual Meeting showed a mean testosterone rise of 4.1 nmol/L in male participants who lost more than 15% body weight [10]. Tirzepatide is a GIP/GLP-1 dual agonist; retatrutide adds glucagon receptor agonism on top of this.

Implications for Finasteride Users

If retatrutide produces testosterone increases in the range of 5 to 8 nmol/L (150 to 230 ng/dL), a man on finasteride 1 mg whose baseline testosterone was already at the lower end of normal might move into a range where his total testosterone is more strong, but his DHT remains suppressed. This is generally a favorable outcome for hair retention, not an adverse one. The risk scenario, though uncommon, is that if DHT suppression is incomplete due to high substrate load and finasteride dose is not adjusted, DHT could drift upward enough to partially undercut the hair-loss benefit.

Key Takeaway for Prescribers

Both retatrutide and finasteride can be used together without dose adjustment based on current PK data. The clinically meaningful consideration is not a drug-drug PK collision but rather a pharmacodynamic shift in the androgen axis driven by substantial fat loss. Monitoring testosterone and DHT at baseline and 12 weeks after reaching the maintenance retatrutide dose (8 mg or 12 mg weekly) allows early detection of any clinically relevant hormonal shift. For men on finasteride 5 mg for BPH, the interaction is likely additive and beneficial. For men on finasteride 1 mg for androgenetic alopecia, DHT monitoring provides the data needed to decide whether dose adjustment is warranted. The Phase 3 TRIUMPH retatrutide program should, when completed, provide larger hormonal sub-datasets that clarify this further.